AllianceBernstein
VYGR icon

AllianceBernstein’s Voyager Therapeutics VYGR Stock Holding History

AllianceBernstein’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Buy
69,050
+10,220
+17% +$38.8K ﹤0.01% 3045
2026
Q1 		$231K Hold
58,830
– – ﹤0.01% 2987
2025
Q4 		$231K Hold
58,830
– – ﹤0.01% 3006
2025
Q3 		$275K Hold
58,830
– – ﹤0.01% 2973
2025
Q2 		$183K Buy
58,830
+22,080
+60% +$71.2K ﹤0.01% 3071
2025
Q1 		$124K Hold
36,750
– – ﹤0.01% 3031
2024
Q4 		$208K Hold
36,750
– – ﹤0.01% 3018
2024
Q3 		$215K Hold
36,750
– – ﹤0.01% 3019
2024
Q2 		$291K Buy
36,750
+21,140
+135% +$177K ﹤0.01% 2920
2024
Q1 		$145K Sell
15,610
-6,320
-29% -$53.4K ﹤0.01% 2985
2023
Q4 		$185K Hold
21,930
– – ﹤0.01% 2996
2023
Q3 		$170K Buy
21,930
+2,690
+14% +$24.6K ﹤0.01% 2991
2023
Q2 		$220K Buy
+19,240
New +$199K ﹤0.01% 2954
2021
Q2 		– Sell
-32,000
Closed -$151K – 3415
2021
Q1 		$151K Sell
32,000
-5,000
-14% -$34.1K ﹤0.01% 3109
2020
Q4 		$265K Hold
37,000
– – ﹤0.01% 2913
2020
Q3 		$395K Sell
37,000
-1,400
-4% -$16.4K ﹤0.01% 2654
2020
Q2 		$485K Buy
38,400
+3,400
+10% +$39.5K ﹤0.01% 2634
2020
Q1 		$320K Buy
35,000
+5,100
+17% +$58.5K ﹤0.01% 2591
2019
Q4 		$417K Hold
29,900
– – ﹤0.01% 2618
2019
Q3 		$515K Sell
29,900
-4,800
-14% -$101K ﹤0.01% 2532
2019
Q2 		$945K Buy
34,700
+1,400
+4% +$32K ﹤0.01% 2334
2019
Q1 		$637K Buy
33,300
+3,900
+13% +$50.8K ﹤0.01% 2432
2018
Q4 		$276K Buy
29,400
+3,100
+12% +$39.8K ﹤0.01% 2770
2018
Q3 		$498K Buy
26,300
+2,500
+11% +$48K ﹤0.01% 2619
2018
Q2 		$465K Buy
23,800
+8,000
+51% +$158K ﹤0.01% 2640
2018
Q1 		$297K Buy
15,800
+3,100
+24% +$67K ﹤0.01% 2704
2017
Q4 		$211K Buy
12,700
+2,200
+21% +$37.7K ﹤0.01% 2849
2017
Q3 		$216K Hold
10,500
– – ﹤0.01% 2902
2017
Q2 		$94K Buy
+10,500
New +$106K ﹤0.01% 3098

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AllianceBernstein's VYGR Position: Q2 2026 in Review

AllianceBernstein increased its Voyager Therapeutics (VYGR) stake by 17% in Q2 2026, buying an estimated $38.8K and bringing the position to 69,050 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

AllianceBernstein first reported a position in VYGR in Q2 2017 and has held it in 29 quarters since. The position peaked at $945K in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • AllianceBernstein held 69,050 shares of Voyager Therapeutics worth $267K as of Q2 2026.
  • AllianceBernstein bought 10,220 Voyager Therapeutics shares in Q2 2026, an estimated $38.8K.
  • Voyager Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3045 holding.
  • AllianceBernstein first reported a position in Voyager Therapeutics in Q2 2017 and has held it in 29 quarters since.
  • AllianceBernstein's Voyager Therapeutics position peaked at $945K in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.